A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0

作者：

Ciuleanu, T. E.

Kurteva, G.

Ocvirk, J.

Beslija, S.

Koza, I.

Papamichael, D.

Vrbanec, D.

Brodowicz, T.

Scheithauer, W.

Zielinski, C. C.

机构：

[1] Inst Oncol Cluj, Cluj Napoca, Romania

[2] Sbalo Natl Oncol Ctr, Sofia, Bulgaria

[3] Inst Oncol, Ljubljana, Slovenia

[4] Inst Oncol, Sarajevo, Bosnia & Herceg

[5] Natl Canc Inst, Bratislava, Slovakia

[6] Banc Cyprus Oncol Ctr, Nicosia, Cyprus

[7] Univ Hosp Rebro, Zagreb, Croatia

[8] Med Univ Vienna, Vienna, Austria

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4032

引用

页数：1